Teva announced the launch of Sildenafil Tablets, the generic version of Pfizer’s Revatio. Revatio is a phosphodiesterase type 5 inhibitor indicated in pulmonary arterial hypertension (WHO Group I) to improve exercise ability and delay clinical worsening.
Sildenafil is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE-5) in the smooth muscle of the pulmonary vasculature, where PDE-5 is responsible for degradation of cGMP. Sildenafil increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with pulmonary arterial hypertension, this can lead to vasodilation of the pulmonary vascular bed and in the systemic circulation.
Sildenafil Tablets will be available in a 20mg strength in 90-count bottles.
For more information call (888) 838-2872 or visit TevaGenerics.com.